Physician profile
Mark D Cohen
NPI 1376545053
$5,248.71
in general payments reported to CMS, 2019-2025
24 companies · $790 in 2025
The $790 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $203 · 2021: $527 · 2022: $1,183 · 2023: $1,761 · 2024: $541 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702 · Travel and Lodging: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,701.89 |
| Travel and Lodging | $389.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,199.16 | 2019-2025 | General - Vascular Access, Watchman Flx |
| Penumbra, INC. | $1,102.75 | 2023 | Indigo System |
| Vanda Pharmaceuticals INC. | $401.22 | 2025 | Ponvory |
| Abiomed | $397.85 | 2022-2024 | Impella |
| Shockwave Medical, INC | $344.49 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $269.78 | 2020-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $262.82 | 2021-2025 | Corevalve Evolut R, Onyx Frontier |
| Edwards Lifesciences Corporation | $254.72 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $214.94 | 2019-2023 | |
| Impulse Dynamics (USA) INC. | $151.09 | 2022-2024 | Optimizer |
| Pfizer INC. | $139.26 | 2022-2025 | |
| Siemens Medical Solutions USA, INC. | $110.28 | 2021 | |
| Kestra Medical Technology Services, INC. | $79.23 | 2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $58.97 | 2019-2024 | Xarelto |
| Livanova USA, INC. | $52.38 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $45.18 | 2024-2025 | Bimzelx, Rystiggo |
| Astrazeneca Pharmaceuticals Lp | $33.00 | 2023 | Farxiga |
| Acist Medical Systems, INC. | $25.99 | 2024 | |
| Ekos Corporation | $24.03 | 2019 | |
| Inspire Medical Systems, INC. | $18.04 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $17.46 | 2023 | Verquvo |
| Angiodynamics, INC. | $16.81 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.95 | 2025 | Jardiance |
| Amgen INC. | $13.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.